Renewable and Specific Affinity Reagents for Mapping Proteoforms in Human Tissues
用于绘制人体组织中蛋白质组图谱的可再生特异性亲和试剂
基本信息
- 批准号:9894469
- 负责人:
- 金额:$ 59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-15 至 2021-08-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAntibodiesAutomationAwarenessBacteriophagesBiologicalCellsCellular StructuresChemicalsColonColorectalConfocal MicroscopyDNADataDevelopmentEpithelial CellsEscherichia coliFab ImmunoglobulinsFluorescent ProbesGrantHealthHumanHuman bodyImageImmunofluorescence ImmunologicIndustrializationInjectionsLaboratoriesMapsMass Spectrum AnalysisMeasurementNamesOutcomePhage DisplayPhosphoserinePhosphotyrosinePost-Translational Protein ProcessingProcessProteinsProteolysisProteomicsReagentRecombinant AntibodyRecombinantsResearch PersonnelResolutionRunningSiteSolidSourceSpatial DistributionSpecific qualifier valueSpecificitySystemTechnologyThreonineTissuesUbiquitinValidationWorkantibody librariescell typehuman tissueimaging modalityinterestmicroscopic imagingmolecular recognitionoverexpressionstoichiometry
项目摘要
Abstract
The mapping of healthy human tissue is an ongoing challenge, critical to which is understanding the cellular
distribution and composition of biomolecules. Among these biomolecules, proteins are perhaps the least
regularized and deeply understood, with their myriad proteoforms created within cells of distinct types. Here, we
outline a new measurement framework poised to better illuminate the underlying cell types and structure defining
solid tissues types in human health and wellness. We propose a two-step process that identifies and
characterizes selected proteins within cells of human tissue and offers the HuBMAP Consortium highly validated
and renewable affinity reagents in the process. Step 1 involves the rapid deployment of previously developed,
recombinant affinity reagents (rABs) and the precise characterization of whole proteoforms in human colon tissue
recognized by them. Step 2 involves the creation of “smart” probes that work on specific post-translational
modifications (PTMs) in a ‘proteoform-aware’ fashion. The result will be specific, renewable and extremely
validated affinity probes that are readily disseminated for use by HuBMAP Tissue Mapping Centers (TMCs).
Importantly, these recombinant antibodies (rABs) will be among the most characterized of any in terms of their
molecular recognition by the end of the three year granting period. This is because of the kind of low-bias readout
that employs “top-down” mass spectrometry (TDMS) to interrogate whole proteoforms and their PTMs directly
(no proteolysis prior to mass spectrometry).
The direct deliverable of this activity will be 30 affinity reagents (20 simple and 10 smart rABs that recognize
PTMs) and hundreds of characterized proteoforms to key targets of high interest to HuBMAP. The affinity
reagents that emerge will be in a recombinant and renewable form (i.e., proven to express in E. coli) that are
ready for use in a variety of imaging modalities through conjugation to fluorescent probes. These will be
applicable to immunofluorescence by confocal microscopy, imaging CyTOF (MIBI), and DNA-barcoded
antibodies to name a few. The stringent process of development and validation represents a general approach
to better map both the chemical space of proteins and their spatial distribution in tissue at cellular and sub-
cellular resolution. Our combined platform focuses on the biologically active forms of proteins (proteoforms) and
the PTMs decorating them that maintain health and wellness in the human body. PTM maps enabled by smart
and renewable reagents represent a high value outcome, templated here through this collaborative effort
between the Wells and Kelleher laboratories both coordinating effectively with each other and the HuBMAP
Consortium.
抽象的
绘制健康人体组织图谱是一项持续的挑战,其中的关键是了解细胞
生物分子的分布和组成。在这些生物分子中,蛋白质可能是最不重要的。
它们在不同类型的细胞内产生了无数的蛋白质形式,从而被规则化并被深入理解。在这里,我们
概述了一个新的测量框架,旨在更好地阐明底层细胞类型和结构定义
人类健康和保健中的固体组织类型。我们提出了一个两步流程来识别和
表征人体组织细胞内选定的蛋白质,并为 HuBMAP Consortium 提供高度验证
以及过程中的可再生亲和试剂。第 1 步涉及快速部署先前开发的、
重组亲和试剂 (rAB) 和人类结肠组织中完整蛋白型的精确表征
得到他们的认可。第 2 步涉及创建作用于特定翻译后蛋白的“智能”探针
以“蛋白质形式感知”的方式进行修饰(PTM)。结果将是具体的、可再生的和极其
经过验证的亲和力探针很容易传播供 HuBMAP 组织作图中心 (TMC) 使用。
重要的是,这些重组抗体 (rAB) 将是最具特征性的抗体之一
在三年授予期结束时进行分子识别。这是因为低偏置读数
采用“自上而下”质谱 (TDMS) 直接询问整个蛋白质组及其 PTM
(质谱分析前无蛋白水解)。
该活动的直接成果将是 30 种亲和试剂(20 种简单 rAB 和 10 种智能 rAB,可识别
PTM)和数百种特征化的蛋白质组,针对 HuBMAP 高度感兴趣的关键靶点。亲和力
出现的试剂将采用重组和可再生的形式(即,证明可以在大肠杆菌中表达)
通过与荧光探针结合,可用于各种成像模式。这些将是
适用于共聚焦显微镜免疫荧光、CyTOF (MIBI) 成像和 DNA 条形码
抗体仅举几例。严格的开发和验证过程代表了一种通用方法
更好地绘制蛋白质的化学空间及其在细胞和亚组织中的空间分布
细胞分辨率。我们的组合平台专注于蛋白质的生物活性形式(蛋白质形式)和
装饰它们的 PTM 可以维持人体的健康。智能启用的 PTM 地图
可再生试剂代表了高价值的成果,通过这种协作努力在此进行了模板化
Wells 和 Kelleher 实验室之间有效地相互协调以及 HuBMAP
财团。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NEIL L KELLEHER其他文献
NEIL L KELLEHER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NEIL L KELLEHER', 18)}}的其他基金
Chemistry of Life Processes Predoctoral Training Program
生命过程化学博士前培训项目
- 批准号:
10628231 - 财政年份:2023
- 资助金额:
$ 59万 - 项目类别:
Multi-Omics And Synbio Enabled Discovery Of Antifungal Fernene Triterpenes
多组学和 Synbio 发现抗真菌蕨烯三萜
- 批准号:
10601431 - 财政年份:2023
- 资助金额:
$ 59万 - 项目类别:
Defining native proteoform landscape for amyloid-beta in Alzheimers disease
定义阿尔茨海默病中β淀粉样蛋白的天然蛋白质形态
- 批准号:
9803611 - 财政年份:2019
- 资助金额:
$ 59万 - 项目类别:
Renewable and Specific Affinity Reagents for Mapping Proteoforms in Human Tissues
用于绘制人体组织中蛋白质组图谱的可再生特异性亲和试剂
- 批准号:
10249071 - 财政年份:2019
- 资助金额:
$ 59万 - 项目类别:
National Resource for Translational and Developmental Proteomics
国家转化和发育蛋白质组学资源
- 批准号:
9456539 - 财政年份:2017
- 资助金额:
$ 59万 - 项目类别:
Mapping and Understanding Production of Natural Products in Fungi
绘制和了解真菌天然产物的生产
- 批准号:
10677824 - 财政年份:2016
- 资助金额:
$ 59万 - 项目类别:
Mass Spectrometric Studies of Thiotemplate Biosynthesis
硫模板生物合成的质谱研究
- 批准号:
9240599 - 财政年份:2016
- 资助金额:
$ 59万 - 项目类别:
Mapping and Understanding Production of Natural Products in Fungi
绘制和了解真菌天然产物的生产
- 批准号:
10522724 - 财政年份:2016
- 资助金额:
$ 59万 - 项目类别:
Mass Spectrometric Studies of Thiotemplate Biosynthesis
硫模板生物合成的质谱研究
- 批准号:
9905491 - 财政年份:2016
- 资助金额:
$ 59万 - 项目类别:
National Resource for Translational and Developmental Proteomics
国家转化和发育蛋白质组学资源
- 批准号:
9283567 - 财政年份:2015
- 资助金额:
$ 59万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 59万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 59万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 59万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 59万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 59万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 59万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 59万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 59万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 59万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 59万 - 项目类别: